Intravenous Dexmedetomidine for Emergence Delirium in Pediatric Patient
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
Various pharmacological interventions in peri-operative period have been used in literature
to prevent ED which include use of propofol, fentanyl, ketamine, clonidine, midazolam and
dexmedetomidine etc (5). Dexmedetomidine is a potent highly selective alpha-2 agonist. Its
effect on the receptors in brain results in sedation resembling non-REM sleep with minimal
respiratory depression (6). It has been used as continuous infusion or as fixed dose in the
range between 0.15 mcg/kg to 2 mcg/kg to prevent ED in children (7, 8, 9). Higher doses
result in better prevention of ED at the expense of more hemodynamic disturbances and longer
PACU stay (9) while lower doses were not as effective (7). The aim of this study was to
investigate the role of fixed dose of 0.2 mcg/kg dexmedetomidine in prevention of emergence
delirium in pediatric patients undergoing general anesthesia.